Compare Abeona Therapeutics Inc (ABEO) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Payoneer Global Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Payoneer Global Inc is far larger — about 6.4× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | PAYO | |
|---|---|---|
Market Cap | $373.32M | $2.40B |
Sector | Health | Technology |
52-Week High | $7.23 | $7.42 |
52-Week Low | $4.17 | $4.27 |
Enterprise Value | $228.22M | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Payoneer Global (PAYO) trades at $7.10, up slightly by 0.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $8.20. Recent financials show revenue growth to $821.16 million in 2025, though net income declined to $73.19 million, and the company is the subject of a pending $2.75 billion acquisition by Nuvei announced in June 2026.
The acquisition offer at $7.40 per share, below the consensus target, creates uncertainty but provides a near-term floor. Risks include integration challenges and shareholder litigation over deal fairness, while fundamentals like a 79.4% gross margin and positive cash flow support long-term value if the deal falls through.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
